Alligator Bioscience AB (publ)

SE-223 81 LUND, V7 · CIK 0001654604 · Biotech · Public

Antibody-based therapeutic drugs for cancer treatment

alligatorbioscience.se →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$10M
1 Form D · Oct 2015
132 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$10,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2512Skyhawk Therapeutics——
2513Nouscom——
2514Somite AI——
2515Alligator Bioscience AB (publ)—$10M
2516Prosetta Biosciences Inc.—$31M
2517Metselex, Incorporated——
2518Radionetics Oncology—$54M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Peter BensonDirector
  • Carl BorrebaeckDirector
  • Claes EricssonDirector
  • Jacob LindbergDirector
  • Kenth PeterssonDirector
  • Jonas SjogrenDirector
  • Mathias UhlenDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.